286 related articles for article (PubMed ID: 32882447)
1. Effect of Aflibercept on Diabetic Retinopathy Severity and Visual Function in the RECOVERY Study for Proliferative Diabetic Retinopathy.
Alagorie AR; Velaga S; Nittala MG; Yu HJ; Wykoff CC; Sadda SR
Ophthalmol Retina; 2021 May; 5(5):409-419. PubMed ID: 32882447
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial.
Wykoff CC; Nittala MG; Zhou B; Fan W; Velaga SB; Lampen SIR; Rusakevich AM; Ehlers JP; Babiuch A; Brown DM; Ip MS; Sadda SR;
Ophthalmol Retina; 2019 Dec; 3(12):1076-1086. PubMed ID: 31542339
[TBL] [Abstract][Full Text] [Related]
3. Correlation between Diabetic Retinopathy Severity and Oxygen Metabolism in Patients with Diabetic Macular Edema during Treatment with Intravitreal Aflibercept.
Blindbæk SL; Peto T; Grauslund J
Ophthalmic Res; 2020; 63(2):106-113. PubMed ID: 31715608
[TBL] [Abstract][Full Text] [Related]
4. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.
Staurenghi G; Feltgen N; Arnold JJ; Katz TA; Metzig C; Lu C; Holz FG;
Br J Ophthalmol; 2018 Jul; 102(7):954-958. PubMed ID: 29051325
[TBL] [Abstract][Full Text] [Related]
5. Prospective Clinical Trial of Intravitreal Aflibercept Treat-and-extend Regimen for Diabetic Macular Edema: 1-Year Outcomes.
Mieno H; Yoneda K; Terao N; Yoshii K; Kojima K; Nagata K; Sotozono C
Korean J Ophthalmol; 2020 Aug; 34(4):290-296. PubMed ID: 32783421
[TBL] [Abstract][Full Text] [Related]
6. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
[TBL] [Abstract][Full Text] [Related]
7. Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Alagorie AR; Nittala MG; Velaga S; Zhou B; Rusakevich AM; Wykoff CC; Sadda SR
JAMA Ophthalmol; 2020 Aug; 138(8):851-857. PubMed ID: 32584384
[TBL] [Abstract][Full Text] [Related]
8. Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes.
Yu HJ; Ehlers JP; Sevgi DD; Hach J; O'Connell M; Reese JL; Srivastava SK; Wykoff CC
Am J Ophthalmol; 2021 Jun; 226():126-136. PubMed ID: 33529593
[TBL] [Abstract][Full Text] [Related]
9. Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.
Dhoot DS; Baker K; Saroj N; Vitti R; Berliner AJ; Metzig C; Thompson D; Singh RP
Ophthalmology; 2018 Jan; 125(1):51-56. PubMed ID: 28764888
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Importance of Changes in Diabetic Retinopathy Severity Score.
Ip MS; Zhang J; Ehrlich JS
Ophthalmology; 2017 May; 124(5):596-603. PubMed ID: 28284785
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Panretinal Leakage and Ischemic Indices in Retinal Vascular Disease after Aflibercept Therapy: The PERMEATE Study.
Figueiredo N; Srivastava SK; Singh RP; Babiuch A; Sharma S; Rachitskaya A; Talcott K; Reese J; Hu M; Ehlers JP
Ophthalmol Retina; 2020 Feb; 4(2):154-163. PubMed ID: 31757691
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
Brown DM; Wykoff CC; Boyer D; Heier JS; Clark WL; Emanuelli A; Higgins PM; Singer M; Weinreich DM; Yancopoulos GD; Berliner AJ; Chu K; Reed K; Cheng Y; Vitti R
JAMA Ophthalmol; 2021 Sep; 139(9):946-955. PubMed ID: 34351414
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
[TBL] [Abstract][Full Text] [Related]
14. Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy.
Wykoff CC; Nittala MG; Villanueva Boone C; Yu HJ; Fan W; Velaga SB; Ehlers JP; Ip MS; Sadda SR;
Ophthalmol Retina; 2022 Jul; 6(7):557-566. PubMed ID: 35257962
[TBL] [Abstract][Full Text] [Related]
15. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
Ozsaygili C; Duru N
Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial.
Kalra G; Wykoff C; Martin A; Srivastava SK; Reese J; Ehlers JP
Ophthalmol Retina; 2024 Feb; 8(2):116-125. PubMed ID: 37696393
[TBL] [Abstract][Full Text] [Related]
17. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
Bahrami B; Hong T; Schlub TE; Chang AA
Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
[TBL] [Abstract][Full Text] [Related]
18. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
[TBL] [Abstract][Full Text] [Related]
19. RETINAL LEAKAGE INDEX DYNAMICS ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY IN EYES TREATED WITH INTRAVITREAL AFLIBERCEPT FOR PROLIFERATIVE DIABETIC RETINOPATHY IN THE RECOVERY STUDY.
Babiuch AS; Wykoff CC; Srivastava SK; Talcott K; Zhou B; Hach J; Hu M; Reese JL; Ehlers JP
Retina; 2020 Nov; 40(11):2175-2183. PubMed ID: 31917731
[TBL] [Abstract][Full Text] [Related]
20. Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
Maturi RK; Glassman AR; Josic K; Baker CW; Gerstenblith AT; Jampol LM; Meleth A; Martin DF; Melia M; Punjabi OS; Rofagha S; Salehi-Had H; Stockdale CR; Sun JK;
JAMA; 2023 Feb; 329(5):376-385. PubMed ID: 36749332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
